Acelyrin Inc. - SLRN Net Assets per Single Share

Acelyrin, Inc. (SLRN) automates the creation of immune molecules using AI and robotics, eliminating routine labor. The book value per common share indicator visualizes net assets, where the value of 4.00 reflects this status. Management is currently reorganizing the portfolio following weak clinical data. Reliance on significant cash reserves allows the company to develop its lead drug independently, ruling out potential mergers.

Acelyrin Inc. (SLRN): Share Book Value from 02/21/2024 to 05/31/2025

acelyrin.com - analytical breakdowns and key metrics (SLRN)

- price and consensus price forecast:
Price Chart ACELYRIN, Inc.|SLRN - Fair Value Consensus
- market capitalization data:
Market Value Acelyrin, Inc.|SLRN - Business Value
- book capitalization data:
Net Assets per Single Share ACELYRIN|SLRN - Net Asset Value|Market Capitalization to Book Value Ratio acelyrin.com|SLRN - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Acelyrin, Inc.|SLRN - Long-Term Debt to Capital|Short-Term Debt to Equity ACELYRIN|SLRN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Acelyrin, Inc.
Fundamental company valuation:ACELYRIN, Inc. - SLRN

For the biotechnology sector company Acelyrin, Inc. (SLRN), which focuses on combating autoimmune pathologies, this indicator serves as a measure of real asset value relative to market hype. By analyzing the book value per share, calculated as the difference between all assets and liabilities, an investor determines the level of fundamental capital protection against volatility during the company's clinical development period.

Competitors of Acelyrin, Inc. (SLRN)

Net Assets per Single Share Haleon Group (HLN)|KVUE: Accounting Value of a Share|Net Assets per Single Share Verona Pharma plc|MENS (jyongbio.com) - Equity per Share|Net Assets per Single Share Ligand LGND|Share Book Value Amneal Pharmaceuticals, Inc.|Perrigo Company (PRGO) - Book Value per Share|Accounting Value of a Share Alvotech Biopharmaceuticals (ALVO)|Book Value per Share LQDA (Liquidia Corporation)|glpg.com - Book Value per Share|Net Assets per Single Share ANI Pharmaceuticals, Inc. (ANIP)|MNKD: Accounting Value of a Share|AMPH (Amphastar) - Net Assets per Single Share|Pacira Corp (PCRX) - Accounting Value per Share|SPRY (ARS Pharmaceuticals) - Book Value per Share|Book Value per Share theravance.com (TBPH)|Aquestive Therapeutics, Inc. (AQST) - Accounting Value per Share|Accounting Value of a Share SCPH (scpharmaceuticals.com)|TECX: Net Assets per Single Share|TNXP - Net Asset Value per Share|Accounting Value per Share SXT China SXTC|EPRX - Book Price of a Share|Book Value per Share BioHarvest Sciences Inc. BHST|Invizyne Technologies (EXOZ) - Accounting Value of a Share|Book Value per Share ORMP (Oramed)|Net Asset Value per Share ENTX|MindWalk Holdings (HYFT) - Net Assets per Single Share|Accounting Value of a Share abvcpharma.com (ABVC)|Book Value per Share CPIX (Cumberland Pharmaceuticals Inc.)|Book Value per Share Quantum BioPharma Ltd. QNTM|FGEN: Book Value per Share|TELO - Accounting Value per Share|Book Value per Share RANI|SNYR (Synergy CHC) - Net Asset Value per Share|Net Assets per Single Share Rallybio Corp|Net Assets per Single Share Lexaria (LEXX)|Pulmatrix Corp - Accounting Value per Share|Net Asset Value per Share PTHL (ftzy.com.cn)|Net Assets per Single Share Aptorum Group|Accounting Value of a Share lyratherapeutics.com LYRA|Book Value per Share IBO (Impact BioMedical Inc)|TNFA: Net Assets per Share|Net Assets per Single Share cbdmd.com|Equity per Share PainReform Corp|CYTO - Accounting Value per Share|Accounting Value of a Share lipella.com|OPTN (OptiNose) - Book Value per Share|Net Assets per Share PIRS (Pieris Pharmaceuticals Inc)|PROC - Net Assets per Single Share|Equity per Share Petros Pharma PTPI|QLI: Book Value per Share|tffpharma.com (TFFP) - Accounting Value per Share